Clinical Care

Most of the largest mortality levers on this site are behavioral: sleep, exercise, diet, smoking cessation, social connection. But a small set of clinical interventions delivers effect sizes that lifestyle alone cannot match in the populations where they matter — testosterone replacement in deficient men with cardiometabolic disease, menopausal hormone therapy initiated within the critical window after menopause, GLP-1 receptor agonists in obesity, statins for elevated apoB, hearing aids for midlife hearing loss. This pillar collects the evidence on those interventions, plus the labs and screening cadences that decide who actually benefits. The voice is the same as everywhere else on the site: what the evidence shows, what's overhyped, and where the limits of current data sit.

What the evidence actually supports

Strong:

• Wilder's Law of Initial Value holds across this pillar: response to a clinical intervention is roughly proportional to how far the patient has drifted from baseline. TRT mortality benefit concentrates in metabolically compromised men (Saad 2024 Andrology registry, HR 0.23 in highest-risk men); GLP-1 MACE reduction is biggest in the obese with established CVD (SELECT 20% MACE); MHT cardiometabolic and mortality benefits concentrate in women initiating therapy within 10 years of menopause. Healthy adults seeking optimization see much smaller absolute benefits, sometimes none.
• The high-value cancer screens — biennial mammography from 40 (USPSTF 2024), colorectal screening from 45 (USPSTF 2021; NordICC 2022), primary HPV every 5 years 30–65, low-dose CT in 50–80 / 20+ pack-year ever-smokers, one-time HCV antibody 18–79, one-time AAA ultrasound for men 65–75 who ever smoked — sit on robust mortality data. The 2023 JAMA Intern Med meta-analysis of 2.1 million participants reframed the rest: across six common modalities, mean life-extension is measured in days, not years.
• Blood pressure — the SPRINT framework. Treating high cardiovascular-risk adults to an intensive systolic target produced a 25% reduction in major cardiovascular events and a 27% reduction in all-cause mortality in SPRINT (9,361 adults). SPRINT-MIND confirmed the cognitive payoff: 19% lower mild cognitive impairment and a durable signal at 7-year follow-up. The 2025 AHA/ACC guideline now codifies treatment from 130/80 for most adults. Home-based monitoring beats one-off clinic readings; isometric wall squats reduce systolic by ~8 mm Hg comparable to first-line drugs; the chronotherapy claim (bedtime dosing) has been definitively settled in the negative by the TIME and BedMed trials.
• Lipid management — apoB-first, cumulative-exposure. The biology of atherosclerosis is the dose × time integral of apoB-containing-particle exposure to the artery wall, and Mendelian-randomization shows up to a 3× greater benefit per unit of LDL lowered when intervention begins earlier. apoB outperforms LDL-C for individual risk because ~25% of adults are discordant; the 2026 ACC/AHA dyslipidemia guideline now recommends apoB testing and universal Lp(a) screening. Statins, ezetimibe (IMPROVE-IT), bempedoic acid (CLEAR Outcomes: 17% MACE reduction in statin-intolerant adults, no diabetes signal), and PCSK9 inhibitors (FOURIER: LDL median dropped from 92 to 30 mg/dL) all work by the same mechanism. SAMSON showed 90% of statin "side effects" are nocebo. The Lp(a) HORIZON trial of pelacarsen reads out in 2026 — the first targeted Lp(a)-lowering therapy.
• Iodine sufficiency is a real longevity input. The Randers-Skagen 20-year cohort showed iodine-replete vs iodine-deficient communities had ~40% lower adjusted mortality (HR 0.60, 95% CI 0.41–0.87). Iodized salt and seafood at the 150 µg/day RDA does the work; kelp/Lugol's megadosing does the opposite. See Thyroid management.
• A short, evidence-based midlife lab panel beats the untargeted annual physical. Randomised data on broad general health checks shows no all-cause-mortality benefit, but a six-marker annual panel (apoB, fasting insulin + HbA1c, hs-CRP, ferritin, uric acid, eGFR), a once-in-a-lifetime Lp(a), and a third-generation epigenetic clock (DunedinPACE) collectively change clinical decisions and track interventions over time. The companion discipline matters as much: refuse NMR lipoprofiles when apoB is available, IgG food panels, salivary "adrenal stress" panels, routine IGF-1 in healthy adults, and provoked heavy-metal challenges.
• TRAVERSE — a 5,204-adult randomised trial published in NEJM in 2023 — settled the decades-old testosterone-and-cardiovascular fear: heart attack, stroke, and cardiovascular death rates were the same on testosterone as on placebo (7.0% vs 7.3%), and the trial also showed a 22.5% reduction in progression to type 2 diabetes. The FDA removed the boxed cardiovascular warning in 2025.
• SELECT — a 17,600-adult NEJM 2023 trial in non-diabetic adults with overweight or obesity and established cardiovascular disease — showed semaglutide 2.4 mg cuts major cardiovascular events by 20%, the first weight-loss drug to deliver a hard cardiovascular outcome.
• The MHT timing hypothesis has been validated prospectively by KEEPS and ELITE: estrogen initiated within 10 years of menopause preserves endothelial function and is associated with ~30–50% lower CHD incidence and roughly RR 0.70 all-cause mortality reduction. Initiated >10 years out, the cardiovascular signal flips. Route (transdermal > oral for thrombotic safety) and progestogen choice (micronized progesterone > MPA / norethisterone for breast safety) are independently decisive. See MHT.
• First-line is lifestyle correction. Both AUA and joint endocrine guidance require optimizing sleep, OSA, exercise, alcohol, and endocrine-disrupting-chemical exposure before any hormone prescription. About 25% of men start TRT without baseline workup — skipping the easiest reversible causes.

Moderate:

• Validated epigenetic-clock deceleration is now a real pharmacological endpoint. A 32-week semaglutide RCT in HIV-lipohypertrophy moved GrimAgeV2 by −2.26 years, OMICmAge by −2.20 years, RetroAge by −2.20 years — the first drug class to do so. Population, dose, and timeframe are all narrow; the signal is real and not yet generalizable.
• The Mendelian-randomization paradox. A 2026 genetic analysis in 425,097 UK Biobank adults found that lifelong genetically predicted higher testosterone increases coronary-artery disease risk in men (~17% higher), mediated by blood pressure. Compatible with TRAVERSE because Mendelian randomization captures cumulative lifelong exposure, not late-life restoration — but it argues against "optimisation" toward 25-year-old levels in healthy adults.
• Don't treat subclinical hypothyroidism in older adults without a specific indication. The TRUST trial (NEJM 2017) — 737 adults aged 65 and over with TSH 4.6–19.99 — showed no benefit from levothyroxine on symptoms, vitality, cognition, grip strength, carotid intima-media thickness, or cardiovascular events. Roughly 58% of mild persistent subclinical hypothyroidism cases revert spontaneously within 3 years. The centenarian inverse and Rotterdam Study additionally argue that a mildly elevated TSH in midlife is adaptive, not a target. See Thyroid management.

Weak / preliminary:

• Microdosing GLP-1 for longevity in healthy adults. Mechanistically plausible (most systemic geroprotective effects may occur at sub-weight-loss doses); zero RCT evidence; compounded supply chain bypasses FDA oversight. Speculative.
• Cognition and mood signals on TRT. A 2025 meta-analysis of 14 RCTs reports SMD 0.49 for executive function and 0.46 for memory in hypogonadal men. AUA still rates the cognitive benefit "inconclusive" (Grade B) — institutional lag behind the meta-analytic data.

Caution:

• TRT secondary signals from TRAVERSE. Atrial fibrillation, acute kidney injury, pulmonary embolism, and modestly elevated blood pressure on ambulatory monitoring. Erythrocytosis (hematocrit >54%) is the single most consistent adverse effect across formulations.
• GLP-1 muscle and bone losses. 25–40% of weight lost is fat-free mass; hip BMD drops ~2.6% at 52 weeks. Without 1.6–2.2 g/kg protein and 2–4 weekly resistance sessions, the drug is a path to sarcopenic obesity, not longevity.
• Compounded prescription medications. Whether semaglutide microdosing or fractionated female testosterone — both bypass FDA oversight on dose accuracy, sterility, and salt formulation. Global consensus discourages compounded female testosterone.
• Overdiagnosis is a real cost of indiscriminate screening. 72–94% of US papillary thyroid cancer diagnoses 1991–2019 were overdiagnoses driven by high-resolution neck ultrasonography of nonpalpable nodules; ~20% of screen-detected DCIS in women 50–75 is overdiagnosis; PSA-detected localized prostate cancer requires ~12 diagnoses to prevent one death. The 2025 ATA guidelines now formally elevate active surveillance for sub-centimeter papillary thyroid cancer. See Cancer screening cadence and Thyroid management.

Practical guidance

1. Correct the reversible inputs first. Sleep, untreated OSA, alcohol, chronic stress, endocrine-disrupting chemicals, and overtraining suppress endogenous testosterone; obesity, sedentary living, and ultra-processed diet drive the metabolic dysfunction GLP-1s rescue. The clinic visit is more useful after these are addressed.
2. Get the baseline lab workup. Annual: apoB, fasting insulin, HbA1c (HOMA-IR), hs-CRP, ferritin, uric acid, CBC, CMP. Once-in-a-lifetime: Lp(a). Symptom-driven only: TSH, two morning testosterone draws, estradiol/FSH. About 25% of men start TRT without this — the most common avoidable mistake in the pillar.
3. Target the middle of the range, not the top. The MR signal on lifelong testosterone, the J-curve on most other hormones, and the Wilder pattern all argue for repletion, not optimization.
4. Scaffold prescription pharmacology with lifestyle, always. GLP-1 without resistance training and 1.6–2.2 g/kg protein is sarcopenic obesity in slow motion. TRT without OSA screening misses the cause. Statins without dietary pattern correction underdeliver.
5. Take the side effects seriously. Hematocrit >54% on TRT, BMD drops on GLP-1, atrial fibrillation signals, and the rare-but-real pancreatitis / gallbladder signal on incretins all warrant active monitoring, not assurance-by-default.
6. Hard contraindications. Pregnancy, MEN2/MTC family history, severe pancreatitis, and active eating disorders rule out GLP-1s. Active prostate cancer is no longer an absolute TRT contraindication post-TRAVERSE, but specialist co-management is the standard. Sex-hormone therapy in adults with breast or hormone-sensitive cancer history needs oncology input.

What's coming

Several adjacent topics live as cross-references in other pillars today and will be developed into dedicated L3 articles as research is provided:

• CAC scoring and advanced cardiometabolic testing — MESA, the "warranty period" of CAC 0, CAC for statin decision in borderline cases, CCTA emerging role (touched on in Lipid management but warrants its own deep dive).
• Cortisol axis (incl. MACS) — Mild Autonomous Cortisol Secretion in adrenal incidentalomas; HPA axis diagnostics; the "adrenal fatigue" debunk vs the real cortisol-flexibility story.
• CGM in healthy adults — Stelo/Lingo OTC era; the spike-anxiety failure mode; thin evidence base for chronic non-diabetic use.

What this category is not

• Not medical advice. The doses, thresholds, and interventions discussed are evidence summaries, not prescribing recommendations. Decisions on a specific patient belong to a specific clinician.
• Not a "preventive optimization" pillar. The site's hierarchy is lifestyle first; this pillar exists because some interventions only happen through a clinician (prescriptions, screening tests, controlled labs), not because pills outperform behavior.
• Not a marketing surface. No brand promotion; the article titles use household names (Ozempic-class drugs) for plain language, not endorsement.

---